Business Context and Reporting Period
This Form 8-K was filed by Pacific Biosciences of California, Inc. on February 15, 2019. The report discloses executive compensation adjustments effective January 1, 2019, following an annual review. The company is currently subject to a proposed acquisition by Illumina, Inc.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation details:
- CEO Base Salary (Michael Hunkapiller): Increased from $1.00 in 2018 to $582,900 in 2019.
- CFO Base Salary (Susan K. Barnes): Increased from $1.00 in 2018 to $401,500 in 2019.
- Target Bonus Opportunities: CEO set at 100% of base salary; CFO set at 65% of base salary.
- RSU Grants: CEO granted 38,750 shares; CFO granted 21,250 shares.
Material Changes Versus Prior Period
The most significant change is the reinstatement of base salaries and bonus opportunities for the CEO and CFO, who previously received only $1.00 in base salary and did not participate in the 2018 bonus plan. This change aligns their compensation with corporate operational, product performance, and financial metrics.
Guidance, Outlook, and Risks
Management Commentary: The compensation plan is designed to be aggressive but attainable, aligning executive interests with company priorities.
Contingencies: The 2019 RSU awards vest on the earlier of the one-year anniversary of the grant date or the completion of the proposed acquisition by Illumina, Inc. Continued service is required through the vesting date.
Investor Verification Checklist
- Verify the status and timeline of the proposed acquisition by Illumina, Inc., as it triggers RSU vesting.
- Review the specific performance objectives and weightings (ranging from 6% to 38%) for the 2019 bonus plan.
- Confirm the total equity value of the RSU grants based on the stock price at the time of grant.
- Check subsequent filings for updates on the acquisition or changes to executive compensation.